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Abstract
Background:  Phytopharmacological studies of different Calendula  extracts have shown anti-
inflamatory, anti-viral and anti-genotoxic properties of therapeutic interest. In this study, we
evaluated the in vitro cytotoxic anti-tumor and immunomodulatory activities and in vivo anti-tumor
effect of Laser Activated Calendula Extract (LACE), a novel extract of the plant Calendula Officinalis
(Asteraceae).
Methods: An aqueous extract of Calendula Officinalis was obtained by a novel extraction method
in order to measure its anti-tumor and immunomodulatory activities in vitro. Tumor cell lines
derived from leukemias, melanomas, fibrosarcomas and cancers of breast, prostate, cervix, lung,
pancreas and colorectal were used and tumor cell proliferation in vitro was measured by BrdU
incorporation and viable cell count. Effect of LACE on human peripheral blood lymphocyte (PBL)
proliferation in vitro was also analyzed. Studies of cell cycle and apoptosis were performed in LACE-
treated cells. In vivo anti-tumor activity was evaluated in nude mice bearing subcutaneously human
Ando-2 melanoma cells.
Results: The LACE extract showed a potent in vitro inhibition of tumor cell proliferation when
tested on a wide variety of human and murine tumor cell lines. The inhibition ranged from 70 to
100%. Mechanisms of inhibition were identified as cell cycle arrest in G0/G1 phase and Caspase-3-
induced apoptosis. Interestingly, the same extract showed an opposite effect when tested on PBLs
and NKL cell line, in which in vitro induction of proliferation and activation of these cells was
observed. The intraperitoneal injection or oral administration of LACE extract in nude mice inhibits
in vivo tumor growth of Ando-2 melanoma cells and prolongs the survival day of the mice.
Conclusion: These results indicate that LACE aqueous extract has two complementary activities
in vitro with potential anti-tumor therapeutic effect: cytotoxic tumor cell activity and lymphocyte
activation. The LACE extract presented in vivo anti-tumoral activity in nude mice against tumor
growth of Ando-2 melanoma cells.
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Background
Plants have a long history of use in the treatment of can-
cer. Active principles of Angelica Gigas, Catharanthus roseus,
Podophyllum peltatum, Podophyllum emodii, Taxus brevifolia,
Ocrosia elliptica, and Campototheca acuminata have been
used in the treatment of advanced stages of various malig-
nancies in the clinical setting [1,2]. Furthermore, many
phytochemicals with different pharmacological proper-
ties have shown responses for the prevention or treatment
of different tumors, e.g., flavones, flavanols, isoflavones,
catechins, and taxanes [3-7]. Numerous drugs are used in
cancer chemotherapy but most exhibit cell toxicity and
can induce genotoxic, carcinogenic and teratogenic effects
in non-tumor cells [8,9]. These side effects limit the use of
chemotherapeutic agents despite their high efficacy in
treating target malignant cells. Therefore, the search for
alternative drugs that are both effective and non-toxic in
the treatment of cancers is an important research line [10].
In fact, increased efforts are being made to isolate bioac-
tive products from medicinal plants for their possible util-
ity in cancer treatment [11].
Flowers of the plant Calendula officinalis, commonly
known as "Marigold", are used in the West and in Asia for
their anti-inflammatory properties [12,13].
Phytopharmacological studies of different calendula
extracts have shown anti-viral activity, anti-HIV properties
of therapeutic interest [14], and anti-genotoxic properties
[15]. In clinical studies, Calendula was highly efficacious
in the prevention of acute dermatitis in cancer patients
undergoing postoperative irradiation [16]. Its cytotoxic
effect on tumor cell lines in vitro and its anticancer effi-
cacy in vivo was briefly outlined 20 yrs ago [17]. Chemical
constituents of C. Officinalis include some triterpenes, trit-
erpene oligoglycosides, and flavonol glycosides [18,19].
The aim of the present study was to evaluate the in vitro
cytotoxic anti-tumor and immunomodulatory activities
of a novel extract of the plant Calendula Officinalis (LACE:
Laser Activated Calendula Extract). We show that LACE
demonstrated a potent in vitro growth inhibition of sev-
eral tumor cell lines, whereas it induced proliferation and
activation of peripheral blood lymphocytes (PBLs). The
mechanisms of this inhibition were identified as cell cycle
arrest and apoptosis induction. Furthermore, the LACE
extract presented anti-tumor activity in vivo in nude mice.
Methods
Preparation of the Calendula Extract (LACE)
The aqueous extract of Calendula officinalis (LACE) was
obtained by subjecting the flower of this plant to the fol-
lowing patented process (patent n° EP 1 339 420 B1).
First, the flowers were washed with water and commi-
nuted by conventional methods. The flowers were treated
with laser radiation at a wavelength of 650 nm for 15 min,
followed by the suspension of 100 to 250 g of laser-
treated plant in 1 L of water. The suspension was placed
on a rocking platform at 4°C for 7–15 days and periodi-
cally treated with laser during this period. Then, the liquid
phase was separated from the solid, an ochre-colored
aqueous extract was obtained and stored in a freezer at -
70°C. A second aqueous extract of Calendula officinalis
was obtained following an identical process but without
laser treatment (calendula extract, CE).
For the assays, the extract was concentrated to dryness in
a lyophilizer, the dried preparation was homogenized in
culture medium at concentration of 10 mg/ml (stock solu-
tion), and filtered through a 0.45 μM Millipore.
Cell lines and cell culture
The following tumor cell lines were used: B16 murine
melanoma, B9 murine MCA-induced fibrosarcoma,
ANDO-2 human melanoma, MDA MB231 human breast
cancer, AGS human gastric cancer, DU-145 human pros-
tate cancer, A-549 human lung cancer, IMIN PC-1 human
pancreatic cancer, DLD1 colon carcinoma, HeLa human
cervical adenocarcinoma, U937 monocytic and Jurkat T
lymphoma leukemias, and NKL, which was established
from PBLs of a patient with LGL leukemia [20]. All cell
lines were obtained from the American Type Culture Col-
lection (Manassas, USA) except for the B9 cell line, which
was generated at our laboratory, and the Ando 2, IMIM
PC-1, and NKL cell lines, kindly provided by P. Coulie
(Unite de Genetique Cellulaire, Louvain University, Brus-
sels, Belgium), F. X. Real (Instituto Municipal de Investi-
gaciones Medicas, Barcelona, Spain), and Dr. M. Lopet-
Botet (Universidad Pompeu-Fabra, Barcelona, Spain),
respectively. Cell lines derived from solid tumors were
grown at 37°C in a humidified atmosphere of 5% CO2 in
DMEM culture medium (Gibco, Paisley UK) supple-
mented with 10% heat-inactivated fetal bovine serum
(Life Technologics, Milan Italy), antibiotics, and
glutamine. U937 and JURKAT leukemia cells were cul-
tured in RPMI. The NKL cell line was cultured in RPMI
1640 with 10% heat-inactivated human AB serum (Sigma
Chemical, St Louis, MO; USA) and human recombinant
IL-2 (1000 U/ml; purity>97%, specific activity, 2 × 106 U/
mg) (Roche, Nutley, NJ; USA).
Lymphocyte proliferation assay
Human lymphocytes were isolated from venous blood by
Ficoll-Hystopaque separation method. Proliferation of
PBLs was analyzed in vitro using 5-bromo-2'-deoxyuridine
(BrdU) labeling of DNA-synthesizing cells with the Brdu
colorimetric ELISA Cell Proliferation kit, (Roche Diagnos-
tics). PBLs were seeded in 96 well-microculture plates at a
cell density of 5 × 104 per well. A dose/response curve was
performed using different concentrations of LACE or CE
(2 mg/ml to 15 μg/ml). Concanavalin A (5 μg/ml, Sigma)BMC Cancer 2006, 6:119 http://www.biomedcentral.com/1471-2407/6/119
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and IL-2 were used as positive control. After 48 h of cul-
ture in presence or absence of LACE, BrdU labeling rea-
gent (final concentration 10 μM) was added and the cells
were cultured during 24 h, then cells were fixed for 30 min
and incubated with anti-BrdU for 1 h at 37°C. 100 μl of
tetramethyl-benzidine (TMB) was used as substrate. Opti-
cal densities were determined at 370 nm using an ELISA
microplate reader (Biotek, Power-Wave XS). Controls
were: culture medium, cells cultured only in medium and
cells incubated with anti-BrdU in absence of BrdU. All
experiments were plated in triplicate wells and were per-
formed at least three times.
In vitro cytotoxicity assays
The effect of LACE or CE on tumor cell proliferation was
assessed by measuring BrdU incorporation with the kit
described above. Cells were plated in 96-well microcul-
ture plates (5 × 103 cells/well). After 24 h of culture at
37°C, a dose/response curve was performed as described
above. Every 48 h, the culture medium was replaced and
LACE or CE was added. After 48–96 h BrdU labeling rea-
gent was added and cultured for a further 1–3 h. Assays
were also performed by counting viable cells using Trypan
Blue exclusion. Briefly, cancer cell lines were seeded into
culture tissue-flask (1.5–2 × 105/culture tissue-flask) or 6-
well plates (NKL cells) and incubated for 24 h at 37°C in
a humidified atmosphere of 5% CO2. Cells were then
treated with 250 μg/ml of LACE in the culture medium,
which was replaced every 48 h. After 4–6 days, the cells
were collected by centrifugation and a small sample of the
cell suspension was diluted in 0.4% Trypan Blue and cells
were counted in a hemocytometer chamber. Each cell
sample was counted in this way at least three times and
each assay was repeated at least three times.
Cell cycle distribution analysis
Briefly, cells were plated in six well plates (5 × 105 per
well) or in culture tissue-flask (15 × 105) and exposed con-
tinuously for 4 days to 250 μg/ml of LACE. The rate of
DNA synthesis was examined by a BrdU incorporation
method using FITC BrdU Flow Kit (BD Pharmingen)
according to manufacturer's instructions. BrdU was then
detected by using a method with DNasa cell treatment
and FITC-conjugated anti-BrdU antibody. Cells were
washed with 1 ml of 1 × BD Perm/Wash Buffer and 20 μl
of 7-amino-actinomycin D was added. Analysis was per-
formed with 50000 cells using Cell Quest Software and
FACScan flow cytometer (Becton-Dickinson).
Analysis of expression of cyclins and cyclin-dependent 
kinases (CDKs)
The cell lines AGS and JURKAT were exposed to 250 μg/
ml LACE during 96–144 hours. The cells were washed
with PBS and permeabilized with Citofix/Citoperm 30
min to 4°C, incubated with anti-cyclin D1 and E antibod-
ies (BD Pharmigen) and finally propidium iodide was
added. The cells were analyzed by inmunofluorescence as
mentioned above.
Western blot analysis was performed for the analysis de
CDK (CDK1/Cdc2, CDK2, CDK4, CDK6) and cyclins (A,
B y D3). The Kit TransFactor Extraction (BD Biosciences)
was utilized to extract whole proteins. Protein samples
were separated by SDS/PAGE (10%) and then electroblot-
ted onto a polyvinylidene difluoride membrane (Kit, Mini
Trans-Blot Electrophoretic Transfer Cell; Bio-Rad). The
membranes were saturated with 5% nonfat dry milk in
TBST (25 mM Tris HCl, 140 mM NaCl and 0.1% Tween
20) and then incubated with anti-CDK1/Cdc2, CDK2,
CDK4, CDK6, cyclin A, cyclin B and cyclin D3 antibodies.
The goat anti-Mouse IgG-HRP (BD Biosciences Pharmin-
gen) was used as the second antibody. The membranes
were washed thoroughly with TBST and incubated for 5 to
30 min with colorimetric solution, Opti-4CN (Bio-Rad,
Madrid, Spain).
Annexin V binding assay to detect apoptotic cells
After treatment of cancer cells with LACE for four days,
cells were detached from the culture tissue-flask with PBS
containing 3 mM EDTA. These cells were then collected
together with floating cells, washed twice with cold PBS,
and resuspended in binding buffer at a concentration of 1
× 106cells per ml. 100 μl of solution was incubated for 30
min at 4°C with 5 μl of Annexin V-PE antibody (BD Bio-
sciences), and 5 μl of 7-amino-actynomycin D was then
added. Cells were incubated for 15 min in darkness, and
400 μl of staining buffer was added before flow cytometry
analysis.
Assay for active caspase-3 expression
FITC conjugated monoclonal anti-active-caspase-3 anti-
body (BD Biosciences) was used to determine whether the
protease Caspase-3 was involved in apoptosis induced by
LACE. After treatment with LACE for 4 days, the cancer
cells were washed twice with cold PBS and fixed and per-
meabilized in Cytofix/Cytoperm buffer. Then, cells were
incubated with FITC-conjugated monoclonal rabbit anti-
active human-caspase-3 antibody for 30 min. Cells were
washed twice and 500 μl of 1 × Perm Wash Buffer was
added before analysis by flow cytometry.
In vivo toxicity assays
For in vivo studies, immunocompetent 6- to 8-week-old
Balb/c, C57/BL6 and CBA mice and 3-month-old Wistar
rats were obtained from the Animal Centre of our institu-
tion. Mean weight of mice and rats was 20 g and 150 g,
respectively. Animals were housed in wire-topped plastic
boxes kept on a 12 hour light/12 hour dark cycle under
pathogen-free conditions. All studies of the animals were
performed according to guidelines approved by our insti-BMC Cancer 2006, 6:119 http://www.biomedcentral.com/1471-2407/6/119
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tution. Animals were randomly divided into groups of 10
mice or rats. LACE extract (0.2 ml) was administered
orally by cannula daily for 5 weeks and the control group
was similarly treated with 0.2 ml water. LACE concentra-
tions used were: 11 mg/kg/day, 55 mg/kg/day, 550 mg/
kg/day, and 2750 mg/kg/day. After 4 weeks of treatment,
the animals were maintained for 4 weeks under standard
conditions and assessed daily for systemic (listlessness,
weight loss) or local (alopecia, skin reaction and leg
motility) toxicity.
Effect of LACE on solid tumor growth in nude mice
Athymic nude mice 6 weeks were obtained from Charles
River (CRL, Barcelona) and all studies of the animals were
performed according to guidelines approved by our insti-
tution. The human melanoma cell line ANDO-2 (5 × 106
cells) was injected subcutaneously at the back foot pad of
mice. When tumors became visible about one week after
injection, the animals were randomized into six groups:
LACE-oral treated (50 mg/Kg of weight), LACE-intraperi-
toneal treated (25 mg/Kg of weight), taxol-intraperitoneal
treated (5 mg/Kg of weight), control, controls treated with
saline solution by oral or intraperitoneal route. LACE was
administered orally three times a week during 12 weeks,
LACE intraperitoneal route twice a week during 9 weeks
and taxol was administered intraperitoneally twice a week
during three weeks. All products were firstly administered
in day 8 after cells injection. Tumor growth (or the long
tumor diameter) was monitored with calipers three times
a week measuring long tumor diameter. Results are
expressed as mean size of tumors from each group ± SD.
Each group was composed of 10 mice and the assays were
performed at least three times. A comparison of the sur-
vival percentage between treated and control group was
performed.
Results
LACE extract exerts mitogenic activity on PBLs
A complete dose-response study was performed to deter-
mine the action of LACE or CE on human PBLs, plating 5
× 104 cells in a 96-well tissue plate for 48–72 h with one
of 8 concentrations of extract as follows: concentration n°
8 = 2 mg/ml, concentration n° 7 = half of concentration
n° 8, and so on successively to a concentration n° 1 of
15.62 μg/ml, with concentration n° 0 representing cells
cultured in medium alone. Fig. 1a depicts the absorbances
when PBLs were incubated with LACE extract, showing a
significant increase in proliferation of PBLs at extract con-
centrations of 125–500 μg/ml. The proliferation induced
by LACE was 3 to 5-fold greater than in the control, reach-
ing 30% of the level of proliferation induced by Concana-
valin A and 50% of the proliferation induced by IL-2 (Fig.
1a). If the results of PBLs proliferation are expressed as
Stimulation index (SI: absorbance of treated lymphocytes
divided by absorbance control or unstimulated lym-
phocytes): SILACE = 2.5, SIIL2 = 4.4, SIconA = 6.5.
Interestingly, LACE induced proliferation without previ-
ous stimulation of PBLs. When these assays were per-
formed using the non laser-treated calendula extract, CE,
the absorbance results were practically identical, indicat-
Dose-response effect of LACE extract in PBLs and B9 fibro- sarcoma murine cell line Figure 1
Dose-response effect of LACE extract in PBLs and 
B9 fibrosarcoma murine cell line. a) PBLs were cultured 
in medium alone or with various concentrations of LACE 
extract from 2 mg/ml (conc. 8) to 15.62 μg/ml (conc. 1) for 
72 h. b) For B9 tumor cells were cultured with culture 
medium alone or various concentrations of LACE or CE for 
72 h. Each column represents the mean of five independent 
experiments ± SD.
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ing that both extracts produce a similar increase in PBL
proliferation (data not shown). The principal chemical
components of the aqueous extracts of Calendula Officina-
lis are: polysaccharides, proteins, fatty acids, carotenoids,
flavonoids, triterpenoids and saponins (data not shown).
LACE extract inhibits in vitro tumor cell proliferation
Exponentially growing cell lines (2.5–5 × 103 cells) were
exposed to increasing concentrations of LACE or CE for
48–72 h in 96-well tissue plates as described above, and a
dose/response curve was performed. Figure 1b depicts
absorbance results when B9 murine fibrosarcoma cells
were cultured with LACE extract. These results showed a
significant decrease in absorbance, mainly in the 125 –
500 μg/ml concentration range, with an IC50 concentra-
tion of 60 μg/ml. Similar results were found for HELA and
Ando 2 cell lines (data not shown). When these assays
were performed with the non laser-treated CE extract, the
decrease in absorbance was notably smaller (Fig, 1b).
These results indicate that CE extract produced signifi-
cantly less inhibition of tumor cell proliferation in com-
parison with LACE extract.
Following these screening assays, LACE extract was used
in further experiments at a concentration of 250 μg/ml.
Similarly results were obtained when other studied tumor
cell lines were cultured with 250 μg/ml of LACE (a
decrease in absorbance was observed with respect to
untreated cells) (Fig. 2). Paclitaxel (Taxol) was used as
control in these experiments, yielding similar results to
those obtained with LACE (Fig. 2). The NKL leukemia cell
line was the exception, since treatment with LACE extract
induced an increase in proliferation. It should be taken
into account that NKL cells are dependent on IL-2 for their
growth and LACE and IL 2 induce similar levels of prolif-
eration.
The correlation between optical densities and number of
viable cells was analyzed, culturing 1–2 × 105 tumor cells
in tissue-flask in medium alone (control) or with 250 μg/
ml of LACE for 4–6 days. As shown in Table 1, there was
a significant decrease in the final number of viable cells,
with a growth inhibition of 70–100% versus control cells,
except for the treated leukemia cell line U937, which
showed a growth inhibition of 21%. Under an inverted
phase contrast microscope, LACE-treated tumor cells
showed morphological changes: rounded and granulated
morphology, some vacuoles coming from cytoplasm, cell
shrinkage and detached from culture plates of a high
number of cells. These morphological changes were not
observed in lymphocytes treated with LACE.
Cell cycle phase distribution analysis of treated cells
Cells were found accumulated in G2/M phase (88.55%)
when PBLs were cultured in medium alone. However,
when PBLs were cultured with addition of 250 μg/ml
LACE, cells re-entered cell cycle, appearing in S phase (Fig.
3). In contrast, when a tumor cell line, e.g., AGS, was cul-
tured in medium alone, cells were in cell cycle (34.68%
G0/G1, 28.66% S, and 17.67% G2/M), and when 250 μg/
ml LACE extract was added, cells showed a significant
accumulation in G0/G1 phase (52.93% of cells) at the
expense of the S phase population (Fig. 3). Similar results
were found in Jurkat cells, where the percentage of LACE-
treated cells in G0/G1 phase was 71.45% (Fig. 3). How-
ever, in other tumor cell lines, e.g., HELA cells, a slowing
rather than an arrest of cell cycle was observed, with a par-
tial accumulation of the cells in G0 /G1 phase (Fig. 3). Frac-
tions of cells in the studied tumor cell lines are listed in
the Table 2.
LACE inhibits expression levels of CDKs- and cyclins-
associated to G1 phase
We have found G1 cell cycle arrest in cells treated with
LACE. The cyclins D1 and E are important regulator of
Table 1: Effect of LACE on growth inhibition in tumor cell lines.
Cell No . (×104)
Initial Control LACE Inhibition
B16 25 440 120 76%
B9 12 120 29 72%
MDA MB231 20 50 20 100%
ANDO 2 20 32 20 100%
A G S 1 53 61 51 0 0 %
D U  1 4 5 1 54 02 27 2 %
HELA 15 25 16 90%
IMIN PC1 15 35 15 100%
A549 16 56 16 100%
DLD1 15 104 30 83%
U937 10 94 78 21%
JURKAT 20 34 20 100%
These results are representative of three independent experiments.BMC Cancer 2006, 6:119 http://www.biomedcentral.com/1471-2407/6/119
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progression through of G1 phase and entry into S phase.
The AGS and JURKAT cells were treated with LACE during
96–144 hours. After this period, a decrease in the expres-
sion of these proteins was detected by immunofluores-
cence (Fig. 4a). The JURKAT cells cultured in alone
medium present an expression of cyclin D1 and E of
36.41% and 87.44%, respectively; when these cells were
cultured with LACE the cyclin D1 expression decrease to
0.88% and the cyclin E expression to 22.09% (Fig. 4a).
Similar results were found in AGS tumor cell line, so the
cyclin D1 expression decreases of 34.56% to 4.11% and
the cyclin E expression decreases of 72.01% to 2.01% (Fig.
4a).
The western blot analyses of total cell lysates showed a
decrease of protein levels of CDK1/Cdc2, CDK2, CDK4,
CDK6, cyclin A and cyclin D3, in LACE-treated cells (Fig.
4b). The cyclin B expression was no altered in response to
LACE (Fig. 4b).
LACE induces apoptosis in tumor cells
Treatment of cancer cells with LACE led to the generation
of a sub-G1 population suggestive of apoptosis. To quan-
titatively examine the ability of LACE to induce apoptosis,
cancer cells were treated with 250 and 1000 μg/ml for 4
days. Cancer cells that were untreated or treated for 4 days
were incubated with Annexin V-PE antibody in a buffer
containing 7-amino-actinomycin D and analyzed by flow
cytometry. Apoptosis of B9 cells increased from 4.32% in
cells cultured in medium alone to 34.47% in those cul-
tured with 250 μg/ml of LACE, and to 60.39% in those
cultured with 1 mg/ml of LACE (Fig. 5). Similar results
were found in the other tumor cell lines (Table 3). In con-
trast, LACE did not produce apoptosis in PBLs (Fig. 5).
Expression of active human caspase-3
Since caspases are the main enzymes involved in the
apoptotic pathway, it was investigated whether active cas-
pase-3 was involved in LACE-induced apoptosis. Thus, the
cancer cell lines were treated with LACE for 4 days, and
cells were then permeabilized, fixed, and stained for active
human caspase-3 and analyzed by flow cytometry. In the
case of AGS cell line, the results clearly illustrated that
untreated cells were primarily negative for presence of
active-caspase-3, whereas around 40% of LACE-treated
cells showed detectable active caspase-3 (Fig. 6). Expres-
sion of active caspase-3 was also detected in other tumor
cell lines, whereas some lines, e.g., HELA, showed no cas-
pase-3 expression after LACE treatment (Fig. 6). These
results indicate that apoptosis in HELA cells was not
induced by caspase-3. In PBLs, as expected, LACE treat-
ment did not induce caspase-3 expression (Fig. 6).
PBL subpopulations activated by LACE
We also analyzed the PBL subpopulations that prolifer-
ated after LACE treatment. Figure 6 depicts representative
results of PBL subpopulations treated with 250 μg/ml
LACE for 72–96 h. In control PBLs, the subpopulations
were 46.27% CD4+, 10.91% CD19+ and 4.94% CD56+/
CD3+. After LACE treatment, these populations signifi-
cantly increased to 59.15% CD4+, 37.71% CD19+ and
92.24% CD56+/CD3+ (Fig. 7). Therefore, cells in prolifer-
ation were mainly B lymphocytes, CD4+ T lymphocytes,
and NKT lymphocytes. Activated CD markers of lym-
phocytes (e.g., HLA-DR and CD69) were expressed by the
lymphocyte subpopulations that proliferated with LACE
treatment (Fig. 7), indicating that these lymphocytes were
activated.
Toxicity of LACE extract in mice and rats
After the above in vitro activities of LACE were established,
investigation of its in vivo toxicity was the next step. In a
preliminary study, Balb/c, C57/BL6, and CBA mice were
orally administered with 11 or 55 mg/kg body weight of
LACE daily for 30 consecutive days and no deaths were
observed during this period. No differences in systemic or
local toxicity were observed between LACE-treated groups
and controls, although a dose increase to 550 mg/kg body
weight resulted in a 50% reduction in the 15-day survival
of these mice (LD50) (data not shown). At autopsy, the
Effect of LACE in proliferation of different cancer cell lines Figure 2
Effect of LACE in proliferation of different cancer cell 
lines. The MDA MB231, B16, ANDO-2, JURKAT, B9 and 
NKL tumor cell lines were treated or not with 250 μg/ml of 
LACE for 72–96 h. MDA MB231 and ANDO-2 were also 
treated with Taxol. Each column represents the mean of five 
independent experiments ± SD.
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animals exhibited hepatic toxicity. LACE was also orally
administered to rats at a dose of 11, 55 and 550 mg/kg
body weight daily for 30 consecutive days, and no deaths
or increases in systemic or local toxicity were observed.
However, when the daily dose was 2750 mg/kg body
weight, 50% of rats died by day 15 (LD50) (data not
shown). After 30 days of treatment, surviving mice and
rats were maintained under standard conditions and their
Cell cycle analysis of cells treated with LACE Figure 3
Cell cycle analysis of cells treated with LACE. PBLs were treated with LACE for 96 h, and cells were analyzed by flow 
cytometry. Similarly, tumor cell lines were treated with LACE for 96 h. Data indicate the percentage of cells in each phase of 
cell cycle. Results are representative of three independent experiments.
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mortality was recorded at 90 days post treatment. During
this period, no toxic side effects, e.g., debility, loss of body
weight or death, were observed.
In vivo anti-tumor effect of LACE
We have established in our laboratory a solid tumor
model with nude mice bearing ANDO-2 human
melanoma cell line. We next investigated the effect of
LACE on this tumor model. The mice administered with
LACE, oral (50 mg/kg of weight) or intraperitoneal (25
mg/kg of weight) route, showed similar tumor growth
inhibition reached to about 60% (Fig. 8a). Similar results
were found with Taxol (Fig. 8a). There was not differences
between the different control groups. The untreated mice
showed a fast progressive increase in tumor volume on the
day 49 while in groups treated with LACE o Taxol
occurred later on day 90 (Fig. 8a).
On the other hand, the survival of mice in LACE-treated
groups was monitored and compared to control groups.
At the end of assays, the survival was: 0% in control
groups, 75% in LACE-oral group, 60% in LACE-intraperi-
toneal group and 40% in taxol group (Fig. 8b).
Discussion
The main finding of the present study is the in vitro anti-
cancer efficacy of a novel extract obtained from Calendula
Officinalis against various cancer cell lines derived from
human or murine solid tumors of different etiologies. In
some cases, this extract, LACE, achieved 100% inhibition
of growth (Fig. 2, Table 1). Importantly, this inhibition
effect is exerted on tumor cells from different solid tumors
and is not specific to a single tumor cell tissue. The in vitro
growth inhibition of LACE extract was similar to that
reported for Taxol in tumor cell lines [21], as shown in
Figure 2.
The principal chemical components of the aqueous
extracts of Calendula Officinalis are: polysaccharides, pro-
teins, fatty acids, carotenoids, flavonoids, triterpenoids
and saponins. The carotenoids components may be
excited by visible radiation. Laser treatment of the calen-
dula extract is necessary to detect this biological activity. A
similar calendula extract without laser treatment, CE, pro-
duced only a slight inhibition of tumor cell growth (Fig.
1b). The increase in this biological activity is due to treat-
ment with laser radiation, which may induce conforma-
tional changes, excitation or degradation of different
molecules of the CE extract.
Studies performed to assess the mechanisms involved in
the above in vitro effects showed that LACE induced cell
cycle arrest in G0/G1 (Fig. 3 and Table 2). Furthermore,
mechanistic investigation showed that LACE-induced G1
arrest mainly mediated via a down-regulation of cyclins
D1, D3, E y A, and CDK1-Cdc2, CDK2, CDK4 and CDK6
(Fig. 4). These novel data may have clinical relevance,
since most human malignancies exhibit aberrations in cell
cycle regulation [22]. In fact, most anticancer agents
derived from plants exert their effect via apoptosis induc-
tion in cancer cells [23-25]. The present data demon-
strated that LACE induces apoptotic death and that the
rate of apoptosis increases with higher LACE concentra-
tions (Fig. 5, Table 3). The induction of apoptosis
involved caspase-3-dependent mechanisms in some but
not all tumor cell lines (Fig. 6), suggesting differential
molecular determinants of apoptosis induction in differ-
ent tumor cell lines.
In leukemia cell lines, LACE treatment inhibited 100% of
growth in Jurkat cells and only 20% of growth in U937
cells, which may be explained by the different origin of
the cells (lymphoma and monocytic, respectively) and/or
the much higher growth rate of U937 cells, which double
in number in less than 24 h. Interestingly, LACE induced
proliferation of NKL leukemia cells (Fig. 2). The NKL cell
line is dependent on IL-2 for its growth in vitro [20], indi-
cating that it is in arrest phase of the cell cycle. Treatment
with IL-2 or LACE produces cell cycle re-entry and similar
proliferation values in NKL cells (Fig. 2). Likewise, a com-
Table 2: Fractions of cells in specific phases of the cell cycle after culture of cancer cell lines in presence or absence of LACE.
DEAD G2 S G1
AGS control 5.77% 17.67% 28.66% 34.68%
AGS LACE 12.24% 16.69% 0% 52.93%
A549 control 9.35% 13.43% 32.13% 29.55%
A549 LACE 8.94% 12.03% 3.40% 44.46%
Jurkat control 22.45% 6.60% 30.59% 26.70%
Jurkat LACE 11.61% 1.42% 0% 71.45%
HELA control 6.59% 14.24% 19.05% 48.58%
HELA LACE 14.77% 9.34% 15.31% 52.19%
B16 control 18.42% 6.13% 27.57% 33.84%
B16 LACE 10.98% 6.21% 4.57% 57.46%
Results are for one typical experiment out of three performed.BMC Cancer 2006, 6:119 http://www.biomedcentral.com/1471-2407/6/119
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pound isolated from the fungus Coriolus Versicolor, Pro-
tein-bound polysaccharide K (PSK), also induces
proliferation of NKL cells in absence of IL-2 [26]. PSK has
shown anticancer activity in vitro in experimental models
and in human clinical trials [27,28]. These anti-tumor
activities can be largely attributed to activation of NK cells
[29,30].
The second novel finding of this study is that LACE treat-
ment induces proliferation and activation of human PBLs
(Fig. 1 and Fig. 7). The CE extract, without laser treatment,
also produces a similar increase in PBL proliferation.
PBLs, which do not proliferate in vitro and are found in
G2/M arrest, re-entered cell cycle with LACE treatment
(Fig. 3).
PBL subpopulations in LACE-induced proliferation were
CD4+, CD19+, and mainly CD3+/CD16/56+ (Fig. 7). The
latter correspond to NKT cells, which have been shown to
recruit and promote a response by downstream effectors
in an IFN-γ-dependent manner, activating both NK and
CTL anti-tumor activity [31,32]. These data, considered
alongside the cytotoxic activity of LACE extract in tumor
cell lines, indicate that it might have anticancer properties
Effect of LACE on cyclins and CDKs Figure 4
Effect of LACE on cyclins and CDKs. The cell lines AGS and JURKAT were cultured in alone medium or treated with 
LACE. a) Flow cytometric analysis was performed for the expression of cyclins D1 and E. The LACE extract produced a strong 
inhibition of expression of both cyclins. b) The western blot analyses showed that LACE produced down-regulation of cyclins 
D3 y A and CDK1/Cdc2, CDK2, CDK4, CDK6. The cyclin B expression was not modified.
Control LACE
JURKAT
36.41%
0.88%
22.09%
Cyclin D1
Cyclin E
Control LACE
34.56% 4.11%
72.01%
2.01%
AGS
Cyclin B
Cyclin D3
CDK1/CDC2
CDK4
CDK2
Cyclin A
87.44%
AGS
AGS-LACE
JURKAT
JURKAT-LACE
AGS
AGS-LACE
JURKAT
JURKAT-LACE
A
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Apoptosis induced by LACE Figure 5
Apoptosis induced by LACE. B9 cell line was untreated or treated with 250 μg/ml or 1 mg/ml of LACE for 96 h. Cells were 
double-stained with annexin V and 7AAD and analyzed by flow cytometry. PBLs were also analyzed and LACE extract did not 
produce apoptosis. All experiments were performed at least three times and gave similar results.
96.24%
4. 32%
62.65%
34.47%
37.06%
60.39%
B9
99.88%
0.11%
99.99%
0.00%
99.98%
0.01%
PBL
CONTROL
LACE  250μg
LACE 1mg
Table 3: Apoptosis induction in cancer cell lines after treatment with LACE for 4 days.
Control LACE 250 μg/ml LACE 1000 μg/ml
B9 4.32% 34% 60.39%
HELA 11.26% 20.32% 56.74%
A549 13.41% 28.84% 36.40%
AGS 20.46% 43% 60%
JURKAT 6% 10.71%
This assay was repeated at least three times, producing similar results.BMC Cancer 2006, 6:119 http://www.biomedcentral.com/1471-2407/6/119
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in vivo. In fact, preliminary results from our laboratory
indicate that LACE can inhibit the growth of mouse tumor
cells in vivo (unpublished results). Results obtained with
PBLs and NKL cells indicate that cells in cell cycle arrest re-
enter cell cycle with LACE treatment. In contrast, LACE
treatment produces phase G1 cell cycle arrest in tumor
cells in cell cycle (Fig. 3). Further research is required to
determine whether a single active principle is responsible
for this dual in vitro activity. Purification of LACE extract is
in progress to identify its active principles. A further find-
ing of this study was the low in vivo toxicity of this extract.
The LD50 for orally administered LACE was 550 mg/kg
body weight in mice and 2750 mg/kg body weight in rats.
Notably, the antiproliferative activity of LACE was not
accompanied by systemic toxicity in mice or rats at a dose
of 50 mg/kg body weight. The LACE extract showed in vivo
anti-tumor activity in nude mice, the growth of Ando-2
tumor was reduced in a 60% (Fig 8). The anti-tumor effi-
ciency of LACE was similar to obtained with other com-
monly used chemotherapy drug, paclitaxel. Furthermore,
LACE produced higher prolongation of lifespan in tumor-
bearing mice (Fig. 8).
Flow cytometric analysis of apoptotic populations using anti-active caspase 3 antibody Figure 6
Flow cytometric analysis of apoptotic populations using anti-active caspase 3 antibody. AGS and HELA tumor cell 
lines were treated with 250 μg/ml or 1 mg/ml of LACE. Data indicate the percentage of cells positive for presence of active-
caspase-3. Results are representative of three experiments
91.88%
4.04%
91.49%
4.56%
92.55%
3.89% PBL
42.22%
37.58% 62.07%
39.41%
94.66%
5.37% AGS
93.80%
3.93%
95%
3.40% 3.33%
94.02% HELA
CONTROL LACE-1mg LACE-250μgBMC Cancer 2006, 6:119 http://www.biomedcentral.com/1471-2407/6/119
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Subpopulation analysis in PBLs treated with LACE Figure 7
Subpopulation analysis in PBLs treated with LACE. PBLs treated or not with LACE were analyzed and results indicate 
an increase in CD4, CD19, and CD3-CD16-CD56 positive cells. This experiment was repeated at least three times and gave 
similar results.
46.27% CD4 59.15% CD4
37.71% CD19 10.91% CD19
4.64% CD56 92.24% CD56
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CD4
CD19
CD5
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DR
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The results of the present study are encouraging because
LACE has shown significant inhibition of tumor growth in
vitro  and  in vivo, therefore LACE or some components
might be a promising chemotherapy candidate in treating
cancers in clinic. Further experiments will focus on purifi-
cation studies and the in vivo efficacy of LACE in other
experimental mouse cancer models.
Conclusion
LACE extract have demonstrated in vitro growth inhibition
of various tumor cell lines. This is due to induction of cell
cycle arrest and apoptosis. In contrast, it induced prolifer-
ation and activation of PBL cells. In addition, LACE
present anti-tumor activity in vivo in nude mice.
Abbreviations
LACE, Laser Activated Calendula Extract; CE, Calendula
extract; PBLs, Peripheral Blood Lymphocytes; LGL, Large
Granular Lymphocyte; TMB, Tetramethyl-benzidine.
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